

## In The Claims

Please amend the claims as follows:

1. (currently amended) A combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least one microcirculation-promoting substance and at least ~~two~~ one active ~~ingredients~~ ingredient which ~~are~~ is selected from at least ~~two~~ of the groups

(a) anti-coagulants, and

(b) vasoprotective agents, and

~~—(c) microcirculation-promoting substances.~~

2. (currently amended) A combined preparation according to claim 1 wherein the active ~~ingredients are selected from the groups anti-coagulants (a) and~~ ingredient includes a vasoprotective agents agent (b).

3. (currently amended) A combined preparation according to claim 1 wherein the active ingredient includes an anti-coagulant. ~~ingredients are selected from the groups anti-coagulants (a) and microcirculation-promoting substances (c).~~

4 - 5 (canceled)

6. (previously presented) A combined preparation according to claim 1 wherein the carrier system is vesicular.

7. (previously presented) A combined preparation according to claim 1 wherein the membrane-forming lipids include the groups of phospholipids, ceramides and diacylglycosides.

8. (previously presented) A combined preparation according to claim 1 wherein the membrane-forming lipids contain at least 70 % by weight of phosphatidylcholine.

9. (currently amended) A combined preparation according to claim 1 3 wherein the anti-coagulants are selected from heparins, fucoidans, hirudins, pentapeptides, coumarin derivatives and mixtures thereof.

10. (currently amended) A combined preparation according to claim 1 9 wherein ~~as the~~ anti-coagulant ~~it~~ contains low molecular weight fucoidan ~~preferably low molecular fucoidan,~~  
~~particularly preferably~~ in an amount of 0.1 – 10 % by weight.

11. (currently amended) A combined preparation according to 1 2 wherein the vasoprotective ~~agents are~~ agent is selected from aescin, rutin, diosmin, ruscogenin and mixtures thereof.

12. (currently amended) A combined preparation according to claim 1 11 wherein it contains aescin as the vasoprotective agent ~~preferably~~ in an amount of 0.1 – 7 % by weight.

13. (currently amended) A combined preparation according to claim 1 wherein the microcirculation-promoting ~~substances are~~ substance is selected from caffeine, naftidrofuryl, pentoxifyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

14. (currently amended) A combined preparation according to claim 1 wherein it contains caffeine as the microcirculation-promoting substance ~~, preferably~~ in an amount of 0.1 - 2 % by weight.

15. (currently amended) A combined preparation according to claim 1 11 wherein ~~it~~ the preparation contains aescin, ~~preferably~~ in an amount of 4.0 to 6.0 % by weight, ~~particularly~~  
~~preferably 5.0 % by weight~~, low-molecular fucoidan, ~~preferably~~ in an amount of 1.0 to 3.0 % by weight, ~~particularly preferably 2.0 % by weight~~, and caffeine, ~~preferably~~ in an amount of 0.5 to 1.5 % by weight, ~~particularly preferably 1.0 % by weight~~.

16. (currently amended) A combined preparation according to claim 1 wherein the carrier system additionally contains linoleic acid in stabilised form, ~~preferably~~ in an amount of 2.5 to 4.5 % by weight.

17. (currently amended) A combined preparation according to claim 1 wherein the preparation further contains at least one thermoreceptor-agonist which is selected from the group ~~which includes consisting of~~ natural or synthetic capsaicin, ~~preferably~~ in an amount of 0.1 to 1 % by weight, ~~particularly preferably in an amount of 0.2 to 0.6 % by weight~~, and nicotinic acid, nicotinic acid amide, nicotinic acid ester or mixtures thereof, ~~preferably~~ in an amount of 0.5 to 5 % by weight, ~~particularly preferably in an amount of 0.5 to 3 % by weight~~.

18. (currently amended) A combined preparation according to claim 1 wherein ~~it~~ the preparation further contains 10 – 25 % by weight of ethanol.

19. (currently amended) A method for the production of a preparation cosmetic or drug according to claim 1, for prophylaxis and/or treatment of hematomas comprising combining membrane-forming lipids and a microcirculation-promoting agent and at least ~~two~~ one active substances ~~which are substance which is~~ selected from ~~at least two of the groups~~ (a) anti-coagulants; and (b) vasoprotective agents. ~~and (c) microcirculation-promoting substances.~~

20. (previously presented) The method of claim 19 wherein the preparation is for prophylaxis or treatment of hematomas of the lower eyelid, and/or veins.

21. (new) A combined preparation according to claim 11 wherein the microcirculation-promoting substance is selected from caffeine, naftidrofuryl, pentoxifyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

22. (new) The combined preparation of claim 21 where the microcirculation promoting substance is caffeine and the vasoprotective agent is aescin.

23 (new) A combined preparation according to claim 22 wherein the preparation contains aescin in an amount of 4.0 to 6.0 % by weight and caffeine in an amount of 0.5 to 1.5 % by weight.